Yusuf D, Walton RN, Hurry M, et al. - For patients with stage III non–small cell lung cancer (NSCLC), researchers analyzed current treatment patterns and outcomes using a population-based patient cohort from a large Canadian province. They assessed 6,438 patients diagnosed with NSCLC, and among those, 1,151 (17.9%) were found to have stage III disease. Only palliative radiotherapy (35.6%), palliative chemotherapy (8.8%), or best supportive care (24.8%) was received as initial treatment by a significant number of patients in this sample. Surgery±adjuvant treatments were received by 14.8% of stage III patients. A median overall survival of 13.2 months was seen in these stage III patients. Statistically significant better survival was observed in patients who received initial curative treatment vs those who received noncurative treatment. Overall, findings demonstrated low use of concurrent chemoradiotherapy and trimodality therapy in stage III NSCLC among community, regional, and tertiary cancer centers in a population-based setting, although evidence showed that these strategies have potential benefits.